Prevention of hepatitis B recurrence after liver transplantation.
Over the last decade significant improvement in patient and graft survival has been observed after liver transplantation for hepatitis B virus (HBV)-related liver disease, mostly because of efficient prophylaxis against hepatitis B reinfection. This review discusses different approches in prevention of hepatitis B recurrence in liver recipients including new concepts as vaccination against hepatitis B after liver transplantation. Based on available data combined prophylaxis with hepatitis B immunoglobulin (HBIG) and lamivudine is currently recommended prophylaxis for HBV recurrence after liver transplantation.
Polak
Wojciech G
WG
Department of Vascular, General and Transplant Surgery, Medical University in Wroclaw, Poland. adalbert@mp.pl
Gładysz
Andrzej
A
Rotter
Katarzyna
K
D000998:Antiviral Agents / Q000008:administration & dosage; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D006509:Hepatitis B / Q000517:prevention & control* / Q000601:surgery*; D017325:Hepatitis B Vaccines / Q000008:administration & dosage; D006801:Humans; D007136:Immunoglobulins / Q000008:administration & dosage; D016031:Liver Transplantation; D055502:Secondary Prevention
D000998:Antiviral Agents; D017325:Hepatitis B Vaccines; D007136:Immunoglobulins; C045213:hepatitis B hyperimmune globulin